
    
      In this trial, patients will receive induction treatment with combination
      chemotherapy(paclitaxel/carboplatin/infusional 5FU) plus bevacizumab. After 6 weeks of
      treatment, patients will be reevaluated and will then receive concurrent radiation therapy,
      chemotherapy (weekly paclitaxel),bevacizumab, and erlotinib.

      Induction Treatment:

      Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over
      1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU
      200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.

      Combined Modality Treatment:

      Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib
      150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel
      50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy
      Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of
      radiation therapy
    
  